2024-10-19 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a global pharmaceutical company specializing in prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return (MRK):** 68.89%
* **Cumulative Return (VOO):** 137.88%
* **Return Difference:** -68.99%
* **Relative Divergence:** 16.28% (This indicates that MRK has underperformed the S&P 500 by a significant margin, but it is currently in the 16.28th percentile of its historical relative performance range.)

**2. Recent Price Trend:**

* **Closing Price:** $108.7
* **5-Day Moving Average:** $110.02
* **20-Day Moving Average:** $111.46
* **60-Day Moving Average:** $114.53

The recent price action indicates a downward trend with the closing price below all three moving averages.

**3. Technical Indicators:**

* **RSI:** 33.67 (This suggests that the stock is in oversold territory, potentially indicating a potential rebound.)
* **PPO:** -0.01 (A negative PPO suggests that the stock price is declining relative to its moving average.)
* **Delta_Previous_Relative_Divergence:** -17.24 (This indicates a recent short-term downward trend in the stock's relative performance compared to the S&P 500.)
* **Expected Return:** 0.0% (The expected return for MRK over the long term (2+ years) is expected to be in line with the S&P 500, based on current market conditions and company performance.)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

The most recent earnings report (2024-08-05) showed an EPS of 2.15, exceeding analysts' estimates by 0.15. Revenue also surpassed expectations, reaching 16.11B$. This strong performance indicates positive growth for MRK.

**5. News and Recent Issues:**

Recent market outlook suggests that MRK is facing potential headwinds due to increased competition in the pharmaceutical market and pressure on pricing. However, the company's robust pipeline of new drugs and its commitment to innovation could drive future growth.

Analyst opinions are mixed, with some expressing concerns about the company's dependence on blockbuster drugs, while others highlight the potential of new product launches. 

**Performance Highlights:**

* MRK has a strong brand recognition and a diversified portfolio of products.
* The company is investing heavily in research and development, with several promising new drugs in its pipeline.
* MRK faces competition from other pharmaceutical giants and generic drug manufacturers.
* Recent regulatory changes in the US and Europe could impact the company's pricing and profitability.

**Overall Analysis:**

MRK has consistently underperformed the S&P 500 in recent years, but its latest earnings beat suggests potential for a turnaround. The stock is currently in oversold territory based on the RSI, suggesting a potential rebound. However, the company faces challenges in a competitive market and faces regulatory pressure. Long-term investors might consider MRK as a potential holding for its strong fundamentals, innovation, and diversified product portfolio, but investors should be aware of the potential risks and volatility. 
